Santiago Moreno Guillén

One oral dose of zoliflodacin—a new antibiotic—is as effective as the current treatment for uncomplicated urogenital gonorrhoea, according to the results of a phase 3 clinical trial published in The Lancet. In some parts of the world, the bacteria that cause gonorrhoea have developed resistance to the current treatment, which combines an injection of ceftriaxone and an oral dose of azithromycin. Zoliflodacin could be an alternative to this treatment, concludes the study, which included 900 people from five countries.

Gonorrhoea is the second most common sexually transmitted disease in the world, with 80 million cases each year. There is no effective vaccine, and the bacteria responsible are becoming resistant to common antibiotics. Some studies have suggested that the meningococcal B vaccine, a unrelated bacterium, may offer partial protection against gonorrhoea. Now, an Italian team has identified 17 antibodies that could explain this cross-immunity, which, according to the authors, could be used to develop treatments and vaccines. The results are published in the journal Science Translational Medicine.